Articles By RheumNow
Reassuring VTE Data for Tofacitinib
By RheumNow
No significant differences in risk for venous thromboembolism (VTE) were seen in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) and those receiving tumor necrosis factor (TNF) inhibitors, analysis of administrative data showed.
Read Article
Rheumatologist and Physician Salaries for 2018
By RheumNow
Medpage Today has published the results of their 2018 Rheumatology Specialty Salaray Survey.
Read Article
TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk
By RheumNow
Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM.
Read Article
Cryotherapy Never FDA Approved
By RheumNow
Another injury related to whole body cryotherapy (WBC) has been reported by practitioners in Philadelphia, serving as yet another warning of WBC's potential to cause serious adverse effects.
Read Article
PRAIRI Study - Can RA Be Prevented?
By RheumNow
B-cell depletion may offer a means of delaying the onset of clinical arthritis in adults at high risk, according to the PRAIRI study - a proof-of-mechanism study in pre-clinical RA patients.
Read Article
High CV Risk in Lupus
By RheumNow
Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.
Read Article
First FDA Approved Drug for HLH
By RheumNow
The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.
Read Article
Subclinical Heart Inflammation Seen in RA
By RheumNow
Subclinical myocardial inflammation is common among patients with rheumatoid arthritis (RA) and is associated with articular disease activity, researchers reported.
Read Article
E/M Guidelines: Right Road, Wrong Direction
By RheumNow
Last July, the Centers for Medicare & Medicaid Services (CMS) proposed new E/M guidelines for office visits with physicians. It issued the final guidelines on November 1, with a few tweaks.
Read Article
Late Breaker: Can Tanezumab Be Revived for OA?
By RheumNow
The monoclonal antibody tanezumab, which blocks nerve growth factor, showed significant benefits in pain and function among patients with osteoarthritis (OA) of the knee or hip, and rates of severe adverse joint events such as rapidly progressive OA that had plagued earlier studies were low, a re
Read Article